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Abstract
This review updates the findings about the anatomical distribution (using immunohistochemical techniques) and 
possible functions of D-glutamate in the central nervous system of mammals, as well as compares the distribution 
of D-glutamate with the distribution of the most studied D-amino acids: D-serine and D-aspartate. The protocol 
used to obtain highly specific antisera directed against D-amino acids is also reported. Immunoreactivity for 
D-glutamate was found in dendrites and cell bodies, but not in nerve fibers. Perikarya containing D-glutamate 
were found in the mesencephalon and thalamus. The highest density of cell bodies was found in the dorsal raphe 
nucleus, the mesencephalic central grey matter, the superior colliculus, and in the subparafascicular thalamic 
nucleus. In comparison with the distribution of immunoreactive cell bodies containing D-serine or D-aspar-
tate, the distribution of D-glutamate-immunoreactive perikarya is less widespread. Currently, the physiological 
actions mediated by D-glutamate in the brain are unknown but the restricted neuroanatomical distribution of 
this D-amino acid suggests that D-glutamate could be involved in very specific physiological mechanisms. In 
this sense, the possible functional roles of D-glutamate are discussed. (Folia Histochemica et Cytobiologica 2017, 
Vol. 55, No. 4, 177–189)
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Introduction
Most amino acids have stereoisomers (L- and D-forms) 
caused by the chiral center on the alpha carbon. In 
the past, it was assumed that in eukaryotes only the 
L-series of amino acids could be found, but currently 
and thanks to advances in analytical techniques, the 
enantiomers of L-amino acids, called D-amino acids, 
have been also found in mammalian tissues, including 
humans [1–6]. These D-amino acids are present in their 
free form or in proteins as D-amino acid residues [1, 3]. 
In mammals, D-amino acids have been located in the 
central nervous system (CNS), in peripheral tissues 
and in physiological fluids [3, 7]. The presence of these 
substances in physiological fluids is influenced by diet, 
physiological state and age [3].
It has been reported that several synthetic and 
natural peptides containing D-amino acids showed 
an antimicrobial activity; these peptides promoted 
the death of cells by the disruption of bacterial mem-
branes [3].
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Free D-amino acids (e.g., D-serine, D-aspartate, 
D-glutamate) are novel physiological substances 
playing important roles in the mammalian central 
nervous system, such as synaptic transmission, neu-
roplasticity, neuronal migration, and brain disorders 
[1, 2, 8–10]. For instance, D-serine is an endogenous 
neuromodulator, since it plays a crucial role in N-me-
thyl-D-aspartate (NMDA) receptor-mediated neuro-
transmission, responsible for memory, learning and 
behavior [1, 3]. In fact, D-serine acts as a co-agonist 
of the NMDA receptor in the brain of mammals [3]. 
It is also known that D-serine inhibits the symptoms 
of the schizophrenia induced by phencyclidine [11], 
and that treatment of schizophrenic patients with 
D-serine, as an add-on agent to other antipsychotics, 
improves negative, positive and cognitive symptoms 
[12]. D-serine has been also involved in the neuro-
pathogenesis of HIV-1 associated neurocognitive 
disorders, epilepsy, Alzheimer’s disease, amyotrophic 
lateral sclerosis, neurotoxicity, ischemia and synaptic 
plasticity, and it has been reported that the extracel-
lular level of D-serine was regulated by the AMPA 
glutamate receptor [3, 13–19]. Moreover, it was found 
that the level of D-serine decreases with age in the 
mouse cerebellum [3].
D-aspartate inhibits melatonin synthesis in the pin-
eal gland and stimulates the expression of vasopressin 
and oxytocin mRNAs, and it was shown that the signif-
icant amount of D-aspartate observed in human and 
rat embryonic brains decreases rapidly after birth [3, 
20–22]. D-aspartate has been located in synaptic vesi-
cles and it seems that this D-amino acid is synthesized 
by the testes and the pituitary gland [3]. D-aspartate 
has been involved in the development of the nervous 
system and in neuroendocrine activities (e.g., D-as-
partate stimulates the release of luteinizing hormone, 
gonadotropin-releasing hormone, growth hormone, 
prolactin, progesterone and testosterone) [3]. It was 
reported that D-aspartate drinking solution alleviated 
pain in neuropathic mice [23] and that this D-amino 
acid is involved in brain aging and spermatogenesis 
[3, 24]. In fact, it is known that age-related changes in 
D-aspartate oxidase promoter methylation regulated 
the extracellular level of D-aspartate, preventing cell 
death during brain aging [25]. D-aspartate has been 
implicated in the regulation of steroid synthesis in the 
brain [26] and in schizophrenia [24, 27, 28]. 
D-glutamate is a potent natural inhibitor of glu-
tathione synthesis. In humans, after the oral admin-
istration of D-glutamate, the concentration of this 
D-amino acid is regulated by two mechanisms: 1) 
transport into cells and its metabolic conversion to 
D-pyrrolidone carboxylic acid and excretion and 2) 
the enhancement of D-glutamate clearance by the 
kidneys [29]. Moreover, D-glutamate is a low-affin-
ity NMDA receptor agonist [30] and it was shown 
that repetitive stimulation of cultured hippocampal 
neurons loaded with D-glutamate caused a dramatic 
shortening of both the rising and decaying phases 
of NMDA receptor excitatory postsynaptic currents 
(EPSCs) evoked by autaptic stimulation [30]. These 
EPSC time courses are mimicked by NMDA receptor 
currents evoked in outside-out patches by application 
of D-glutamate. This means that D-glutamate is re-
leased as a false transmitter [30]. 
The relationship between pathophysiological pro- 
cesses and the brain content of D-amino acids has 
been also increasingly recognized: D-amino acids are 
present at significantly higher levels in the cerebrospi-
nal fluid (CSF) of patients suffering from Alzheimer’s 
disease, but this finding was not observed in the CSF 
of patients affected by multiple sclerosis [1, 31]. In an 
experimental model of Alzheimer’s disease it has been 
reported that, compared with control rats, the levels 
of D-leucine, D-alanine, D-proline and D-serine, in 
hippocampus and cerebral cortex were significantly 
decreased [15].
The generation of D-amino acids  
and methods of their detection in tissues  
and body fluids
In most cases, D-amino acids are produced by race-
mization from their corresponding enantiomer antip-
odes by the action of racemases and for this reason 
amino acid racemases play a central role in D-amino 
acid metabolism. The conversion of L-amino acids 
to D-amino acids occurs because these racemases 
change the stereochemistry of the chiral alpha-carbon 
in amino acids [3]. Most amino acid racemases require 
pyridoxal 5’-phosphate as a coenzyme, but several 
other require no coenzymes [32]. It should be noted 
that many reports indicate that exogenous D-amino 
acids, derived from food and bacterial cell walls, could 
be distributed in mammalian tissues [1]. D-amino 
acids are degraded by the flavoenzyme D-amino acid 
oxidase through a process of oxidative deamination, 
and the D-amino acid oxidase regulation of D-amino 
acid levels has been associated with hormone secre-
tion, synaptic transmission, and cognition [3]. In fact, 
D-amino acid oxidase activity is increased in patients 
with schizophrenia compared with healthy ones [33]. 
In general, the amount of D-amino acids in tissues 
is quite low and hence sensitive and selective methods 
such as high-performance liquid chromatography, 
gas chromatography, high-performance capillary 
electrophoresis, and enzymatic methods are required 
for their detection and measurements [15, 34–39]. 
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Thus, using these methods, the presence of D-alanine, 
D-proline, D-leucine, D-phenylalanine, D-glutamine, 
D-tyrosine, D-tryptophan, D-Lysine, D-threonine and 
D-valine has been reported in mammalian tissues and 
physiological fluids (e.g., brain, liver, kidney, pituitary 
gland, blood, urine) [1]. In addition, thanks to the 
development of highly specific antibodies against 
D-amino acids, the anatomical distribution of some 
D-amino acids (D-serine, D-glutamate and D-aspar-
tate) has been widely reported in the mammalian 
CNS [1, 2, 8, 40–45]. The presence of other D-amino 
acids such as D-tryptophan, D-cysteine, D-tyrosine or 
D-methionine was studied in rat brain, but no immu-
noreactive structures containing these D-amino acids 
were observed [44].
All the foregoing shows that there are many data in 
the literature about the presence in tissues of D-serine 
and D-aspartate, as well as about the functions in 
which both D-amino acids are involved. These two 
D-amino acids are the most abundant D-amino acids 
in mammals [3]. However, the distribution of D-glu-
tamate in the mammalian CNS and the functions in 
which this D-amino acid is involved have been less 
studied. It is important to apply immunohistochem-
istry (IHC) to investigate the tissue distribution of 
D-amino acids, because this technique shows which 
cells contain such substances and where D-amino 
acids are located inside the cells (cell body, dendrites, 
nerve fibers). IHC allows the determination of the 
neuroanatomical distribution of D-amino acids in 
order to gain insight into the possible roles that these 
substances play in the areas of the CNS in which they 
are located. To achieve these goals, highly specific an-
tisera against D-amino acids must be obtained. Thus, 
in this review, we update the information about the 
anatomical localization of D-glutamate in the mam-
malian CNS and possible physiological roles played by 
this D-amino acid. The distribution of D-glutamate is 
compared with the distribution of both D-serine and 
D-aspartate and, finally, the development of new tools 
(highly specific antisera against D-amino acids) for the 
study of these substances is also reported.
How to obtain highly specific antibodies 
directed against D-amino acids?
D-glutamate is a small molecule with a molecular 
weight below 1 kDa (MW 147.13). Small molecules 
are not immunogenic, so they are usually linked 
through a coupling agent (e.g., aldehydes, carbod-
iimides, picric acid) to a carrier protein [46, 47], since 
the immune response is triggered by molecules with 
a mass 1 to 2 kDa, which is the minimum size for 
stimulating antibody production. Animals receiving 
the immunogen (D-glutamate-coupling agent-carrier 
protein) will generate different types of polyclonal 
antibodies, some of which will recognize the con-
jugated D-glutamate, while other populations will 
recognize the carrier protein or the coupling agent. 
Antibodies directed against the carrier protein and 
the coupling agent could give a spurious signal that 
must be blocked, reduced or suppressed by later 
purification and checked after application of the 
respective controls. 
The choice of the coupling agent is very impor-
tant in order to maintain the original structure and 
conformation of D-glutamate and hence it should be 
ensured that the D-glutamate coupled to the carrier 
protein is identical to that found in the tissue. When 
glutaraldehyde is used as the coupling agent, a re-
ducing agent such as sodium borohydride, NaBH4, 
is necessary to reduce the imine groups. Moreover, 
this agent transforms the double bonds generated 
during the linkage process into saturated (single) 
bonds, providing the molecule (e.g., D-glutamate) 
with a spatial conformation that is generally identical 
to that of the molecule in vivo. Thus, NaBH4 enables 
saturation of the imine double bonds [46]. This is 
very important in such studies that use IHC in which 
the antibodies must recognize a specific target. This 
protocol is readily applicable both at the in vitro and 
at tissue level [8, 44, 46]. In vitro: the antigen used 
for the immunization of the animals is reduced with 
NaBH4 (the molecules used for the immunization 
must be the same as those that will be assayed later 
in vitro or in the tissue); hence, the antigen used to 
characterize the antibody affinity and specificity sites 
were evaluated using the Enzyme Linked Immuno-
sorbent Assay (ELISA) test. In tissue: after perfusion 
of the animals and processing of the tissue, the slices 
are reduced with NaBH4 to localize the molecule in 
its original conformation in the tissue. This process 
is also easy to use in tissues fixed with glutaraldehyde 
(immunocytochemical techniques): the background is 
reduced since the immunogen used and the molecules 
located in the tissue have the same conformation [44, 
46]. Thus, the reduction of the sections with NaBH4 
increases the specificity of the immunocytochemical 
reaction [44, 48], allows a spatial change of the anti-
gen, and enables the antibody site to better recognize 
the three-dimensional structure of the antigen due to 
a change in the molecular orbital from Sp2 to Sp3 [46]. 
The tissue treatment described here should be always 
carried out when D-glutamate has been linked via glu-
taraldehyde to a carrier protein [44, 46]. According to 
the above, it must be confirmed that the antigen (e.g., 
D-amino acid), that will be used for the immunization 
of the animals, was not modified during the linkage 
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procedure [46]. This is important, for ethical (in or-
der to use a lower number of animals) and technical 
reasons (to avoid generation of unspecific antibodies 
generated by an incorrect linkage or a modification of 
the targeted molecule) [46]. Therefore, the chemical 
structure of the antigen used for immunization is 
usually controlled by spectrophotometry (ultraviolet 
and/or infrared) [44, 46]. 
The development of new and highly specific anti-
bodies directed against D-amino acids has increased 
the knowledge on the field (e.g., D-glutamate, D-ser-
ine, D-aspartate) according to the protocol carried 
out by our group [44, 46]. D-glutamate was dissolved 
in acetate buffer and a second solution was prepared 
containing bovine serum albumin (BSA), also dis-
solved in the same buffer (Fig. 1). To conjugate the 
D-glutamate with BSA, a glutaraldehyde solution 
was added to the first solution (containing dissolved 
D-glutamate). The coupling reaction produced yellow 
color and the addition of NaBH4 rendered the solu-
tion translucent (Fig. 1). The NaBH4 saturated the 
double bonds, and after the mixture became totally 
translucent, the saturation reaction was over. This 
final solution was dialyzed against distilled water. 
Then, rabbits were immunized every two or three 
weeks over two months (Fig. 1). Each subcutaneous 
administration was a mixture of a fresh immuno-
genic conjugate (reduced D-glutamate-glutaralde-
hyde-BSA) and of complete or incomplete Freund 
adjuvant, depending on whether it was the first 
immunization or consecutive ones. After the second 
immunization, serum samples were obtained. Anti-
sera were preabsorbed with reduced and lyophilized 
BSA-glutaraldehyde in order to remove antibodies 
directed against the conjugated carrier protein and 
neutralize possible spurious signals in later applica-
tions such as ELISA or IHC. After this process, the 
antisera must be centrifuged and the floating phase 
must be purified. Antisera must be tested before 
and after the purification process in order to evalu-
ate possible alterations that might occur during the 
purification process, and no changes in the signal 
or specificity of the antibodies must be found as a 
consequence of the pre-purification process.
ELISA tests are used to evaluate the antibodies 
present in the antisera. In order to obtain an adequate 
characterization, it is crucial to get the titration val-
ues before to carry out the competition experiments 
(Fig. 1). This is done at 492 nm and the best dilution 
is obtained when the optical density is around 1 
[44, 47]. For example, in the case of D-glutamate, 
several optical densities are obtained for several 
concentrations of the antibody (dilution 1/40,000: the 
optical density was 0.5; dilution 1/20,000: 1; dilution 
1/10,000: 2; dilution 1/5,000: 3). The IC50 is the point 
to be reached and this occurs when there is enough 
competitor to decrease the optical density to 0.5. This 
value is important because it will be used to obtain 
the avidity of the antibody for a specific target (e.g. 
D-glutamate) (Fig. 1). In order to obtain the affinity 
of the antibodies directed against D-amino acids, 
several solutions containing an identical concentra-
tion of the antiserum (e.g. D-glutamate at 1/10,000) 
are tested using several concentrations of the antigen 
(e.g. conjugated D-glutamate at 10-3 M, 10-4 M etc.). 
The avidity of the antibody is high when, at a low 
concentration of the antigen (lower than 10-7 M), the 
optical density (antibody signal) disappears (Fig. 1). 
By the use of different antigens the specificity of the 
antibody is determined (Fig. 1, Table 1). Small dif-
ferences in chemical structures (e.g., different spatial 
conformations of the same molecule, chemical groups, 
and/or chain lengths) are required to determinate the 
specificity of the antibody (see Table 1 and 2).
The estimated antibody avidity (IC50) is fairly 
high (10-8 M for anti-conjugated D-glutamate and 
10-11 M for anti-conjugated D-serine and D-aspartate 
antibodies). Moreover, the specificity of the three 
anti-conjugated D-amino acids antibodies was very 
high, because the antisera discriminated very well 
closely conjugated structures. For D-glutamate, the 
competitors tested were the following: L enantiomer 
of glutamate, both enantiomers of glutamine and 
aspartate, D-cysteine, D-methionine, D-tryptophan, 
D-tyrosine, taurine and GABA (Table 1). For D-ser-
ine: L enantiomer of serine, both enantiomers of D-as-
partate, D-cysteine, D-alanine, L-glutamate, L-glu-
tamine, GABA, glycine, and taurine (see Table 1) 
and for D-aspartate: L enantiomer of aspartate, both 
enantiomers of glutamate, and N-methyl-D-aspar-
tate (see Table 2). No cross-reactivity was observed 
with the molecules studied. An important fact is 
that anti-conjugated D-glutamate antibodies do 
not recognize the L enantiomer (L-glutamate) or 
D-glutamine, which is known to be synthesized in 
glial cells from D-glutamate [49]. All the conjugate 
coupled by a glutaraldehyde bond was reduced. This 
means that no spurious immunoreactivity could be 
considered, since the antiserum is preabsorbed with 
reduced glutaraldehyde-BSA before application of 
ELISA and/or immunocytochemical techniques and 
that the antibody is specific to the reduced conjugated 
D-glutamate. That is, the conjugated D-amino acids 
studied were reduced and were identical to those 
conjugated molecules used for the immunization of 
the animals. In summary, the antisera recognized spe-
cifically the targeted D-amino acids, since antibodies 
did not present cross-reactivity with analogous close 
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structures, even when comparing D/L enantiomers 
(Table 1 and 2).
Neuroanatomical distribution  
of D-amino acids
Using an HPLC technique, the presence of free D-glu-
tamate in the rat brain was first reported in 1995 [38].
Those authors also demonstrated for the first time the 
presence of free D-glutamate in rat liver and kidney 
and that the treatment of tissue extracts with D-as-
partate oxidase mostly abolished the HPLC peaks of 
D-glutamate. The same authors also reported that the 
content of free D-glutamate was lower in females than 
in males [38]. However, before using highly specific 
antibodies directed against D-glutamate developed 
Figure 1. The procedure of developing highly specific antibodies against D-glutamate (see text).
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by GEMAC S.A. (Saint Jean d’Illac, France), the 
mapping of immunoreactive structures containing this 
D-amino acid was not carried out in the mammalian 
brain until 2007 [44]. In that study, only perikarya/ 
/dendrites containing D-glutamate were seen in the 
rat brain, since no D-glutamate-immunoreactive 
fibers were found. Immunoreactivity was confined 
to neuronal structures, whereas non-neuronal cells 
were devoid of immunoreactivity. The distribution 
of the D-glutamate-immunoreactive cell bodies was 
very restricted, since these cell bodies were only found 
in rat mesencephalon and thalamus in the following 
nuclei/regions: the nucleus of Darkschewitsch, the 
dorsal and ventral parts of the mesencephalic cen-
tral grey, the medial habenular nucleus, the superior 
colliculus, the dorsal raphe nucleus (Fig. 2A–D), 
the posterior thalamic nuclear group, the subpara-
fascicular thalamic nucleus and above the rostral 
linear nucleus of the raphe and the posterior com-
missure (Table 3). Moreover, a cluster of D-gluta-
mate-immunoreactive cell bodies was located below 
the medial forebrain bundle. In general, cell bodies 
containing D-glutamate were small (10–14 µm in 
diameter), round or fusiform, and showed none to 
three short-medium-length dendrites [44]. It should 
be noted that the distribution and number of such 
immunoreactive cell bodies differed, depending on 
the protocol followed for the immunocytochemical 
technique. In that study [44], two different protocols 
for IHC were followed. In the first, the sections were 
reduced with a solution of sodium borohydride prior 
to carrying out the immunocytochemical protocol 
[48], whereas in the second protocol the reduction 
procedure was not carried out. Applying the first 
method, antibodies recognized the three-dimensional 
structure of the antigen (D-glutamate) better [46, 48]. 
When the sections were reduced with sodium borohy-
dride, more nuclei in the central nervous system of the 
rat showed immunoreactivity (that is, the distribution 
was more widespread than when such sections were 
not reduced) and, in addition, a higher number of 
immunoreactive perikarya containing D-glutamate 
was observed, in the same nucleus, in NaBH4-reduced 
sections than in unreduced ones [44]. 
In the immunohistochemical studies, in order to 
confirm the specificity of the immunoreactivity it is 
very important to carry out adequate histological 
controls. The specificity of the immunocytochemi-
cal techniques used is not absolute, and the validity 
of the results should always be checked with other 
techniques. The affinity and specificity of antibodies 
directed against D-amino acids must be tested using 
ELISA tests and they must also be studied under the 
same conditions with different competitors in each 
particular case.
The immunoreactivity for D-glutamate was always 
confined to neuronal structures (dendrites and cell 
bodies), but the presence of other D-amino acids 
Table 1. Affinity and specificity of antibodies directed against 
conjugated D-glutamate and D-serine
Compound Cross reactivity at  
half-displacement (IC50)
D-Glutamate competitors
D-Glutamate-G-BSA
L-Glutamate-G-BSA
*Glutamine-G-BSA
*Aspartate-G-BSA
D-Cysteine-G-BSA
D-Methionine-G-BSA
D-Tryptophan-G-BSA 
D-Tyrosine-G-BSA
Taurine-G-BSA
GABA-G-BSA
D-Serine competitors
D-Serine-G-BSA
L-Serine-G-BSA
D-Cysteine-G-BSA
D-Alanine-G-BSA
L-Glutamic acid-G-BSA
L-Glutamine-G-BSA
*Aspartate-G-BSA
GABA-G-BSA 
Glycine-G-BSA 
Taurine-G-BSA
BSA 
1
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1
1/10,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
1/50,000
Using competition ELISA assays, cross-reactivity was calculated from the 
displacement curves at half-displacement: the best recognized conjugates 
were D-glutamate-G-BSA and D-Serine-G-BSA, respectively, whose con-
centration was divided by the concentration of each of the other conjugates. 
G — glutaraldehyde. *Means that L and D enantiomers were tested and the 
results were identical.
Table 2. Affinity and specificity of antibodies directed against 
conjugated D-aspartate
Compound Cross-reactivity  
at half-displacement (IC50)
D-Aspartate-G-BSA 1
L-Aspartate-G-BSA 1/10,000
N-Methyl-D-Aspartate 1/50,000
*Glutamic acid-G-BSA 1/50,000
BSA 1/50,000
Using competition ELISA assays, cross-reactivity was calculated from the 
displacement curves at half-displacement. The best recognized conjugate was 
D-Aspartate-G-BSA, whose concentration was divided by the concentration 
of each of the other conjugates. G — glutaraldehyde. *Means that L and D 
enantiomers were tested and the results were identical.
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such as D-serine has been found in neurons (axons, 
dendrites and cell bodies) and glial cells [8, 40, 41]. 
The differences regarding the presence of various 
D-amino acids inside neurons are unknown, although 
the location of D-glutamate exclusively in dendrites 
and cell bodies could be due to the lack of axonal 
transport mechanisms of this D-amino acid, as it is 
known to occur for some neuroactive substances 
(e.g., somatostatin) [50]. Moreover, the distribution 
of D-glutamate- and D-serine-immunoreactive cell 
bodies in the mammalian brain (Table 3) seems 
to be quite different, since cell bodies containing 
D-serine have been located in the cerebral cortex, 
hippocampus, olfactory bulb, vestibular nuclei, infe-
rior colliculus, motor trigeminal nucleus, trapezoid 
body, dorsolateral geniculate nucleus (Fig. 3A–D) 
and in the superior olivary complex [8, 40, 41]. In 
those regions, no cell bodies containing D-gluta-
mate were observed [44] and, by contrast, in those 
regions in which cell bodies containing D-glutamate 
were observed (e.g., dorsal raphe nucleus, mesen-
cephalic central grey, superior colliculus, nucleus of 
Darkschewitsch, medial habenular nucleus), no cell 
bodies containing D-serine were found. The presence 
of fibers containing D-serine has been observed, for 
example, in the medial and lateral ventroposterior 
thalamic nuclei (Fig. 3E), the dorsolateral genicu-
late nucleus, and in the medial geniculate nucleus. 
D-serine immunoreactive perikarya were small- or 
medium-sized, round, pyramidal or fusiform, whereas 
unbranched and smooth D-serine-immunoreactive 
fibers were short- or medium-sized in length. After 
the preabsorption of the anti-conjugated-D-serine 
antibody with D-serine-glutaraldehyde-BSA, the 
immunoreactivity disappeared (Fig. 3F). No immu-
noreactive cell bodies containing D-glutamate [44] 
have been described in any of the above-mentioned 
thalamic nuclei containing D-serine (Table 3).
D-aspartate-immunoreactive neurons (small- 
or medium-sized, round or fusiform) were found 
in the rat brain in the interpeduncular nucle-
us, the inferior olive, the cochlear nuclei, the 
hypoglossal nucleus, the facial nucleus, the 
cerebellum, the paraventricular hypothalamic 
nucleus, the supraoptic nucleus (Fig. 4A, B), 
the medial habenular nucleus (Fig. 5A–C), the ol-
factory bulb, hippocampus and in the septal nuclei 
[51] (Table 3). This distribution is quite different 
from that of cell bodies containing D-glutamate 
[44] or D-serine [8, 40, 41]. Thus, the distribution of 
Figure 2. D-glutamate-immunoreactive cell bodies in the rat dorsal raphe nucleus (DR) (A–D). B. High-power magnification 
of cell bodies containing D-glutamate located in the region demarcated in Figure 2A. D. High-power magnification of the 
region demarcated in Figure 2C. The anti-conjugated D-glutamate-BSA (reference: AP030) was provided by GEMAC S.A. 
(France) (see Table 1). Abbreviations: AQ — aqueduct; D — dorsal; M — medial.
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the neuronal populations containing D-glutamate, 
D-serine or D-aspartate is different in the rat brain 
(Table 3). Moreover, in comparison with the distri-
bution of the immunoreactive structures containing 
either D-serine or D-aspartate in the rat brainstem, 
the distribution of D-glutamate is less widespread. 
It should be noted that cell bodies containing D-as-
partate were described in the medial habenula [51], 
and in this nucleus the presence of D-glutamate-im-
munoreactive cell bodies has been also reported [44] 
(Table 3).This means that a possible coexistence of 
both D-amino acids could occur in this thalamic nu-
cleus. This could be demonstrated in future studies.
Functional roles of D-amino acids  
and future studies 
D-serine and D-aspartate play important roles in 
the mammalian CNS system (e.g., neuronal migra-
tion, synaptic plasticity, NMDA receptor-mediated 
neurotransmission, neurotoxicity, inhibition of me-
latonin synthesis, pain, brain aging, stimulation of 
oxytocin synthesis, regulation of steroid synthesis) 
and they are also involved in brain disorders (e.g., 
schizophrenia, epilepsy, amyotrophic lateral sclero-
sis, Alzheimer’s disease) [1–3, 8, 9, 11–13, 15, 18–20, 
22–24, 26–28, 52].
Table 3. Neuroanatomical distribution of D-glutamate-, D-serine- and D-aspartate-immunoreactive cell bodies in the rat brain
D-glutamate D-serine D-aspartate
Cerebellum – – +
Cerebral cortex – + –
Cochlear nuclei – – +
Dorsal raphe nucleus + – –
Dorsolateral geniculate nucleus – + –
Facial nucleus – – +
Hippocampus – + +
Hypoglossal nucleus – – +
Inferior colliculus – + –
Inferior olive – – +
Interpeduncular nucleus – – +
Lateral ventroposterior thalamic nucleus – + –
Medial geniculate nucleus – + –
Medial habenular nucleus + – +
Medial ventroposterior thalamic nucleus – + –
Mesencephalic central gray + – –
Motor trigeminal nucleus – + –
Nucleus of Darkschewitsch + – –
Olfactory bulb – + +
Paraventricular hypothalamic nucleus – – +
Posterior thalamic nuclear group + + –
Septal nuclei – – +
Subparafascicular nucleus + – –
Superior colliculus + – –
Superior olivary complex – + –
Supraoptic nucleus – – +
Trapezoid body – + –
Vestibular nuclei – + –
The table summarizes data presented in the text and Figures 2–5.
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The neuroanatomical data reported above indicate 
that D-glutamate has a very restricted anatomical 
distribution in the rat brain; although the possibility 
that the immunohistochemical techniques used might 
be insufficiently sensitive to visualize all the profiles 
containing D-glutamate in the brain cannot be ruled 
out. It is possible that other neuronal structures might 
contain low levels of D-glutamate, undetectable with 
the technical approach used. The restricted distribu-
tion of D-glutamate suggests that this D-amino acid 
could be involved in very specific actions that will have 
to be addressed in the future. However, according 
to the anatomical distribution reported for D-glu-
tamate in the rat brain, this D-amino acid could be 
involved for example in auditive, visual and analgesic 
mechanisms, since D-glutamate-immunoreactive cell 
bodies were observed in the superior colliculus and in 
the mesencephalic central grey [44]. The presence of 
Figure 3. D-serine-immunoreactive cell bodies in the rat dorsolateral geniculate nucleus (A–D). B. High-power magnifica-
tion of cell bodies containing D-serine located in the region demarcated in Figure 3A. D. High-power magnification of the 
region demarcated in Figure 3C. E. D-serine-immunoreactive nerve fibers in the lateral ventro-posterior thalamic nucleus. 
F. Low-power magnification of the dorsolateral geniculate nucleus after preabsorption of the first antibody. (The preabsorp-
tion of the first antibody with the corresponding antigen: if the signal is avoided, it demonstrates that there’s no background 
or spurious signal and that signal visualized corresponds to specific signal of the first antibody, means specificity). Note 
the absence of immunoreactive cell bodies. Arrows indicate immunoreactive cell bodies. Abbreviations: D, dorsal; DLG, 
dorsolateral geniculate nucleus; M, medial; VLG, ventrolateral geniculate nucleus; VPL, lateral ventroposterior thalamic 
nucleus. This Figure is published with the permission of GEMAC S.A. Laboratories. The anti-conjugated D-serine-BSA 
(reference: AP041) was provided by GEMAC S.A. (France) (see Table 1).
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D-glutamate in the medial habenula nucleus suggests 
that this D-amino acid could be involved in learning, 
memory, attention, sleep/wake cycles and anxiety 
[53–55]. Moreover, D-glutamate could be involved 
in other functions in the rat brain nuclei in which cell 
bodies containing this D-amino acid were observed. 
It was demonstrated that D-glutamate is a weak, 
although effective, competitor for a L-glutamate 
transporter cloned from glial cells [49], an effective 
substrate for a low-affinity glutamate uptake system 
[49] and is taken up into glial cells and converted into 
D-glutamine [49], this substance being exported from 
glial cells and taken up by neurons [30]. Moreover, 
D-glutamate was shown to be a potent natural inhib-
itor of glutathione synthesis [49] and a low affinity 
Figure 5. D-aspartate-immunoreactive cell bodies in the 
medial habenula (A, B). B. High-power magnification of 
cell bodies containing D-aspartate located in the region 
demarcated in Figure 5A. C. Low-power magnification 
of the habenular complex after preabsorption of the first 
antibody. Note the absence of immunoreactive cell bodies. 
Arrows indicate immunoreactive cell bodies. Abbreviations: 
D — dorsal; LHb — lateral habenula; M — medial; MHb 
— medial habenula; PV — paraventricular thalamic nucleus; 
sm — stria medullaris thalamus; V — ventricle. This Figure is 
published with the permission of GEMAC S.A. Laboratories. 
The anti-conjugated D-aspartate-BSA (reference: AP024) 
used was provided by GEMAC S.A. (France) (see Table 2).
Figure 4. D-aspartate-immunoreactive cell bodies in the 
supraoptic nucleus (A, B). B. High-power magnification 
of cell bodies containing D-aspartate located in the region 
demarcated in Figure 4A. Arrows indicate immunoreactive 
cell bodies. Abbreviations: D — dorsal; L — lateral; SO 
— supraoptic nucleus. This Figure is published with the per-
mission of GEMAC S.A. Laboratories. The anti-conjugated 
D-aspartate-BSA (reference: AP024) used was provided by 
GEMAC S.A. (France) (see Table 2).
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NMDA receptor agonist [30]. These data suggest that 
the physiological role played by D-glutamate present 
in the rat mesencephalic and thalamic neurons should 
be addressed in future studies.
An accumulation of D-glutamate in neurons located 
in the mesencephalon and thalamus of the rat has also 
been reported, suggesting that these neurons have 
a mechanism for the uptake of D-glutamate [44]. Thus, 
incubation of rat brain slices with D-glutamate in-
creased D-glutamate immunoreactivity in comparison 
with the immunoreactivity observed in perfused fixed 
rat brain sections (not incubated with D-glutamate) 
and in comparison with the results (no immunoreac-
tivity) found in rat brain sections not incubated with 
D-glutamate (brain slice experiments) [44]. It should 
be noted that when rat brain slices were treated with 
D-glutamate (brain slice experiments), immunoreac-
tive cell bodies were observed and these cell bodies 
showed the same distribution in the rat central nervous 
system when compared with the immunoreactivity seen 
in perfused fixed rat brain sections (not incubated with 
D-glutamate). This suggests that the D-glutamate pres-
ent in cell bodies could act as a false neurotransmitter 
that is exported to the extracellular space and that 
could be taken up by neurons [44]. Other authors have 
also suggested that D-glutamate is released as a false 
transmitter [30], although the absence of D-glutamate 
in nerve fibers and terminals argues against a possible 
transmitter role of this D-amino acid. Thus, the action 
of D-glutamate as a neurotransmitter is a point that 
will have to be addressed in the future.
The neuroanatomical distribution of D-glutamate 
in the rat brain suggests that it may play hitherto un-
suspected roles and hence be a candidate for novel 
physiologically active substances. Future neuroana-
tomical and physiological studies should be carried 
out to collect more data and gain further insight into 
the functional roles of D-glutamate in the rat brain. 
Such studies should attempt to unravel whether D-glu-
tamate acts as a neuromodulator/neurotransmitter. 
Moreover, it would be very interesting to study the 
distribution of D-glutamate and other D-amino acids 
in the human/monkey brain using new, highly specific 
antisera directed against them.
To sum up, our knowledge of D-glutamate function 
in the mammalian CNS is still quite limited. The advent 
of high-affinity and high-specificity antisera directed 
against each conjugated D-amino acid, whose discrim-
ination between the L- and D- enantiomers, as well as 
other molecules, guarantees specific recognition of 
a given D-amino acid. By using immunohistochemical 
techniques D-amino acids can be readily visualized, 
and such approach will increase our understanding 
of D-amino acids function of in the mammalian CNS.
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